Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients

Surgery Today

Volumn 41, Issue 8, 2011, Pages 1067-1074

  Suenaga, Mitsukuni ^a   Matsusaka, Satoshi ^a   Ueno, Masashi ^a   Yamamoto, Noriko ^a   Shinozaki, Eiji ^a   Mizunuma, Nobuyuki ^a   Yamaguchi, Toshiharu ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bevacizumab; Carbohydrate antigen 125; Colorectal cancer; Irinotecan; KRAS

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; MALE; METASTASIS; MUCOSAL BLEEDING; NAUSEA; ORAL BLEEDING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEINURIA; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052407055     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-010-4432-8     Document Type: Article

References (22)

1. H. Hurwitz L. Fehrenbacher W. Novotny T. Cartwright J. Hainsworth W. Heim, et al. 2004 Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
2. B.J. Giantonio P.J. Catalano N.J. Meropol P.J. O'Dwyer E.P. Mitchell S.R. Alberts, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 17442997 10.1200/JCO.2006.09.6305 1:CAS:528:DC%2BD2sXlsVyntbc%3D (Pubitemid 46733080)
3. L.B. Saltz S. Clarke E. Diaz-Rubio W. Scheithauer A. Figer R. Wong, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
4. F.F. Kabbinavar J. Schulz M. McCleod T. Patel J.T. Hamm J.R. Hecht, et al. 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 3697 3705 15738537 10.1200/JCO.2005.05.112 1:CAS:528: DC%2BD2MXlslWntr0%3D
5. Bennouna J, Husseini F, Delord JP, Borg C, Trillet-Lenoir V, Faroux R, et al. Bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: Results from the phase II BEVACOLOR study. ECCO 15 and 34th ESMO Multidisciplinary congress, Berlin, Germany; September 22-24, 2009 (abstract 6074).
6. H. Konno M. Yamamoto M. Ohta 2010 Recent concepts of antiangiogenic therapy Surg Today 40 6 494 500 20496129 10.1007/s00595-009-4150-2
7. C. Tournigand T. Andre E. Achille G. Lledo M. Flesh D. Mery-Mignard, et al. 2004 FOLFORI followed by FOlFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 14657227 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
8. K. Blackwell H. Hurwitz G. Liebérman W. Novotny S. Snyder M. Dewhirst, et al. 2004 Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma Cancer 101 77 82 15221991 10.1002/cncr.20336 1:CAS:528:DC%2BD2cXlvFCnu7s%3D (Pubitemid 38812425)
9. V. Formica M.C. Massara I. Portarena V. Fiaschetti I. Grenga G. Del Vecchio Blanco, et al. 2009 Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients Cancer Biomark 5 167 175 19729826 1:CAS:528:DC%2BD1MXht1Ggu77J
10. W. Reiter P. Stieber C. Reuter D. Nagel U. Lau-Werner R. Lamerz 2000 Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer Anticancer Res 20 5195 5198 11326694 1:STN:280: DC%2BD3M3ovVSluw%3D%3D (Pubitemid 32319106)
11. Yang XQ, Li Y, Chen C, Peng CW, Liu SP, Liu Y. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer. Med Oncol 2010; DOI: 10. 1007/s12032-010-9518-z [epub ahead of print].
12. B.W. Yin A. Dnistrian K.O. Lloyd 2002 Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene Int J Cancer 98 5 737 740 11920644 10.1002/ijc.10250 1:CAS:528:DC%2BD38Xis1Wru7o%3D (Pubitemid 34225625)
13. N.S. Azad C.M. Annunziata S.M. Steinberg L. Minasian A. Premkumar C. Chow, et al. 2008 Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy Cancer 112 8 1726 1732 18300236 10.1002/cncr.23374 1:CAS:528:DC%2BD1cXls1Gkt7o%3D (Pubitemid 351536832)
14. R.A. Burger M.W. Sill B.J. Monk B.E. Greer J.I. Sorosky 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 5165 5171 18024863 10.1200/JCO.2007.11.5345 1:CAS:528:DC%2BD2sXhsVKnsb%2FE (Pubitemid 350237599)
15. J.D. Wright A.A. Secord T.M. Numnum R.P. Rocconi M.A. Powell A. Berchuck, et al. 2008 A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer Int J Gynecol Cancer 18 3 400 406 17645510 10.1111/j.1525-1438.2007.01027.x 1:STN:280: DC%2BD1czhtlWiug%3D%3D (Pubitemid 351668295)
16. M. den Ouden J.M. Ubachs J.E. Stoot J.W. van Wersch 1998 Thrombinantithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours Scand J Clin Lab Invest 58 7 555 559 10.1080/00365519850186175 (Pubitemid 29016381)
17. R. Gaetje D.W. Winnekendonk A. Ahr M. Kaufmann 2002 Ovarian cancer antigen CA 125 influences adhesion of human and mammalian cell lines in vitro Clin Exp Obstet Gynecol 29 1 34 36 12013089 1:STN:280:DC%2BD383mvFKrtA%3D%3D (Pubitemid 34298510)
18. S. Kopetz P.M. Hoff J.S. Morris R.A. Wolff C. Eng K.Y. Glover, et al. 2010 Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 453 459 20008624 10.1200/JCO.2009.24.8252 1:CAS:528:DC%2BC3cXivFartLY%3D
19. C.S. Karapetis S. Khambata-Ford D.J. Jonker C.J. O'Callaghan D. Tu N.C. Tebbutt, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 18946061 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J
20. W. De Roock H. Piessevaux J. De Schutter M. Janssens G. De Hertogh N. Personeni, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 17998284 10.1093/annonc/mdm496 (Pubitemid 351325672)
21. W.L. Ince A.M. Jubb S.N. Holden E.B. Holmgren P. Tobin M. Sridhar, et al. 2005 Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 981 989 15998951 10.1093/jnci/dji174 1:CAS:528:DC%2BD2MXlvF2hsL8%3D (Pubitemid 41430564)
22. H.I. Hurwitz J. Yi W. Ince W.F. Novotny O. Rosen 2009 The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 22 28 19144677 10.1634/theoncologist.2008-0213 1:CAS:528:DC%2BD1MXjt1Clt7o%3D